-
Faeth Therapeutics names two SVPs ahead of clinical milestones
-
Faeth Therapeutics, Inc. (FTH) Tops Q2 EPS by 132c
-
Jones Trading Starts Faeth Therapeutics (FTH) at Buy
-
Raymond James Starts Faeth Therapeutics (FTH) at Outperform
-
Oppenheimer Starts Faeth Therapeutics (FTH) at Outperform
-
Citizens Starts Faeth Therapeutics (FTH) at Market Outperform
-
Baird Starts Faeth Therapeutics (FTH) at Outperform
-
H.C. Wainwright Starts Faeth Therapeutics (FTH) at Buy
-
faeth (FTH) files mixed shelf

